Cytotoxicity testing of medical polymer materials is the essential first step in the biocompatibility evaluation of polymer-based medical devices, verifying that leachable substances such as residual monomers, plasticizers, additives and sterilization residues do not harm living cells. Performed in accordance with ISO 10993-5, GB/T 16886.5 and USP Chapter 87 using methods such as the MTT extract assay, direct contact and agar diffusion tests, it is a mandatory data element for FDA, EU MDR and NMPA submissions. This guide explains the technical basis, sample preparation, test methods, acceptance criteria and practical applications of cytotoxicity testing for medical polymers.
Technical Overview
Cytotoxicity testing is the cornerstone in vitro biological evaluation for medical polymer materials. Its purpose is to determine whether a material, or substances extracted from it, produces toxic effects on cultured mammalian cells. As the first test in the ISO 10993 evaluation sequence, it provides a rapid, sensitive and cost-effective screening of biological risk before any animal-based testing is undertaken. For polymer-based products such as infusion sets, catheters, implants, wound dressings and primary packaging, cytotoxicity data are a mandatory element of regulatory submissions in virtually every major market.
Medical polymers are chemically complex systems. Even when the base resin is biologically inert, toxicity can originate from residual monomers and oligomers, plasticizers, heat stabilizers, antioxidants, colorants, processing aids, adhesive and ink residues, sterilization by-products such as ethylene oxide, and degradation products released during hydrolysis or oxidation. Because these leachables can migrate into surrounding tissue or circulating blood, in vitro cytotoxicity assessment using standardized cell culture models remains the most practical first line of defense for patient safety.
Regulatory and Standards Framework
- ISO 10993-5, Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity, the internationally recognized method standard.
- ISO 10993-12, defining sample preparation, extraction ratios, extraction vehicles and reference materials.
- ISO 10993-1 together with ISO 10993-18 and ISO 10993-17, which frame cytotoxicity testing within the overall biological evaluation plan, chemical characterization and toxicological risk assessment.
- GB/T 16886.5, the Chinese national standard technically aligned with ISO 10993-5, required for NMPA device registration.
- USP Chapter 87, In Vitro Biological Reactivity Tests, frequently requested for polymeric materials and pharmaceutical packaging in the North American market.
- JIS T 0993 series, the Japanese national adoption of the ISO 10993 framework.
Testing is carried out by accredited third-party laboratories or qualified in-house biosafety facilities operating under GLP-aligned quality systems. Results are accepted in support of FDA 510(k) and PMA submissions, EU MDR conformity assessment, NMPA registration and PMDA applications.
Testing Samples
Practically any polymeric article intended for patient contact, or any material intended for incorporation into such an article, can be evaluated. Samples should represent the final production condition, including the intended sterilization process, because sterilization can introduce cytotoxic residues or alter leachable profiles.
Typical Sample Forms
- Finished devices: syringes, infusion and transfusion sets, intravenous catheters, blood bags, stopcocks, dialysis cartridges, endotracheal tubes and anesthesia breathing circuits.
- Polymeric components: PVC tubing, polyethylene and polypropylene films, silicone elastomer seals and gaskets, polyurethane membranes, PEEK machined parts, polycarbonate and ABS housings.
- Bioresorbable materials: PLA and PLGA scaffolds, absorbable sutures, drug-eluting carriers and matrices.
- Surface-modified and coated articles: hydrophilic lubricious coatings, antimicrobial layers, tissue adhesives, printed labels and inks on fluid-path components.
- Raw materials for screening: base resins, masterbatches, compounding ingredients and candidate formulations during research and development.
- Primary packaging and container closure systems: blister films, liner materials, plastic ampoules and closures contacting the device or dose path.
Sample Preparation and Extraction
Extraction is performed according to ISO 10993-12. Representative portions are cut aseptically and extracted at standardized ratios of surface area or mass to extraction vehicle volume:
- Material thickness less than 0.5 mm: 6 cm² per mL of extraction vehicle.
- Material thickness 0.5 mm to 1.0 mm: 3 cm² per mL.
- Material thickness greater than 1.0 mm: 1.25 cm² per mL.
- Irregularly shaped solids: 0.1 g to 0.2 g per mL.
The extraction vehicle is selected for compatibility with the cell assay; serum-supplemented minimum essential medium (MEM) is most common for cytotoxicity, while physiological saline, water for injection, ethanol–water mixtures or DMSO are used for special materials. Standard extraction conditions include 37 °C for 24 h or 72 h, 50 °C for 72 h, 70 °C for 24 h and 121 °C for 1 h. The condition is chosen according to the thermal stability of the polymer; for example, plasticized PVC is typically extracted at 37 °C to 50 °C so that exaggerated heat does not produce an artificially aggressive leachate profile. Each run includes validated controls: high-density polyethylene as the negative control and zinc diethyldithiocarbamate (ZDEC), natural rubber latex or Triton X-100 as positive controls.
Testing Items
Depending on the selected method and endpoint, a cytotoxicity study quantifies one or more of the following items:
- Cell viability expressed as a percentage of the negative control, the primary quantitative endpoint.
- Metabolic activity measured by tetrazolium reduction assays (MTT, XTT, WST-1) or resazurin (Alamar Blue) reduction.
- Lysosomal function measured by neutral red uptake (NRU).
- Total cell protein or biomass determined by kenacid blue or crystal violet staining.
- Cell membrane integrity assessed by LDH release or dye exclusion.
- Cell morphology, attachment and growth inhibition scored on the qualitative reactivity scale of grade 0 to grade 4.
- Proliferative capacity and colony-forming efficiency determined by clonogenic assay.
- Dose–response behavior across serial extract dilutions, typically 25%, 50% and 100% extract.
Commonly used cell systems include the L929 mouse fibroblast line, which is the most widely applied per ISO 10993-5, as well as BALB/3T3 and V79 cells. Human-derived lines such as MRC-5, WI-38 or HaCaT may be justified where the clinical contact nature warrants a more relevant cell type.
Testing Methods
Extract Test (Elution Method)
The extract test is the most widely applied approach for medical polymers. Cells are seeded in multiwell plates, exposed to 100%, 50% and 25% extract dilutions for 24 ± 2 h, or up to 72 h where scientifically justified, and then evaluated with a quantitative endpoint such as MTT. The method detects both polar and non-polar leachables, accommodates almost any sample geometry and permits dose–response analysis.
MTT Colorimetric Assay
Viable cells with functional mitochondria reduce the yellow tetrazolium salt MTT to purple formazan crystals. After solubilization in DMSO or isopropanol, absorbance is read at approximately 570 nm. Viability is calculated as the absorbance of the extract-exposed wells divided by that of the negative control, expressed as a percentage. The MTT assay is the default quantitative option of ISO 10993-5 and is valued for its objectivity, reproducibility and 96-well throughput.
Direct Contact Test
The specimen is placed directly onto a confluent cell monolayer for 24 h. Toxic leachables diffusing from the material cause lysis, malformation or detachment of cells beneath and around the sample, which are graded microscopically from 0 (no reactivity) to 4 (severe reactivity). The method is suitable for films, elastomeric pieces and low-density materials whose weight does not mechanically injure the monolayer.
Agar Diffusion (Agar Overlay) Test
A thin layer of agar-supplemented medium is placed over the monolayer, and the sample is set on the agar surface. Diffusible toxicants pass through the agar while the cells are protected from mechanical damage. The response is scored as a zone index and lysis index. This method is preferred for elastomeric closures, high-density materials and samples that would otherwise crush the cells.
Filter Diffusion Test
Cells are grown on a cellulose acetate membrane and exposed to the test sample or its extract. The method detects diffusible toxicants from complex, composite or irregular samples and is useful when standard direct contact and agar overlay configurations are impractical.
Neutral Red Uptake and MEM Elution
Viable cells incorporate neutral red dye into lysosomes, and uptake is measured photometrically at approximately 540 nm. This endpoint is a standard option for plastics evaluation under USP Chapter 87 and is equally acceptable as a quantitative option under ISO 10993-5.
Acceptance Criteria
- Quantitative evaluation: cell viability of 70% or greater relative to the negative control in the 100% extract indicates the sample is non-cytotoxic; viability below 70% indicates a potential cytotoxic effect that must be investigated through dilution series and dose–response analysis.
- Qualitative evaluation: reactivity is graded from 0 (none) to 4 (severe). Grades 0 and 1 generally satisfy the requirements, grade 2 is assessed case by case, and grades of 3 or above indicate cytotoxicity.
- Test validity: the positive control must produce a clearly cytotoxic response and the negative control must remain viable; otherwise the run is rejected and repeated.
Applications
Regulatory Submission and Market Access
Cytotoxicity reports are a core element of biological evaluation files for FDA submissions, EU MDR technical documentation, NMPA registration dossiers and PMDA applications. A valid study demonstrates conformity with ISO 10993-5 or GB/T 16886.5 and supports the overall biological safety justification required for market authorization of polymer-based devices.
Material Screening and Formulation Development
During R&D, comparative cytotoxicity testing ranks candidate resins, plasticizer systems, stabilizer packages, colorants, coatings and adhesives before tooling investment. Early screening prevents costly redesign late in development and accelerates selection of inherently safe material platforms.
Change Control and Post-Market Surveillance
Changes in resin supplier, formulation, processing conditions, cleaning agents, sterilization method or primary packaging can alter the leachable profile. Repeat cytotoxicity testing, sometimes combined with chemical characterization under ISO 10993-18, verifies that such changes do not compromise biological safety. Typical product categories covered include:
- Vascular access and infusion therapy: IV catheters, syringes, infusion sets, extension tubing, stopcocks and blood bags.
- Implantable polymers: PEEK spinal and orthopedic implants, silicone devices, polymer bearings in joint prostheses and hernia repair meshes.
- Extracorporeal circuits: dialyzer housings, oxygenator components and blood tubing sets.
- Wound care: hydrocolloid and foam dressings, hydrogels and tissue adhesives.
- Ophthalmic products: contact lens materials, intraocular lens components and viscoelastic packaging.
- Dental materials: composite resins, denture base polymers and orthodontic appliances.
- Drug delivery and combination products: inhaler components, prefilled syringe closures and drug-eluting matrices.
- Pharmaceutical packaging: blister films, liner materials, plastic ampoules and container closure systems.
FAQ
Which standard governs cytotoxicity testing of medical polymer materials?
ISO 10993-5 is the primary international method standard, supported by ISO 10993-12 for sample preparation. In China, GB/T 16886.5 is the equivalent national standard required for NMPA registration, while USP Chapter 87 is frequently cited for plastics and packaging in the North American market.
Which cell line is most commonly used?
The L929 mouse fibroblast line is the most widely used cell system because it is well characterized, robust in culture and broadly accepted by regulators. BALB/3T3, V79 and human-derived lines are also accepted when scientifically justified.
How much sample is needed for a test?
The required amount follows the ISO 10993-12 extraction ratios. For example, at 3 cm² per mL, a surface area of 30 cm² yields 10 mL of extract, which is sufficient for a standard multi-dilution MTT study. For irregular solids, typically 5 g to 10 g of material is submitted depending on the test design.
How long does the test take?
A standard extract-based MTT test, including extraction, cell seeding, exposure and evaluation, is usually completed within 7 to 10 working days. Studies involving multiple extraction vehicles, several methods or extended exposure periods may require two to four weeks.
What does a result below 70% viability mean?
A viability value below 70% of the negative control indicates a potential cytotoxic effect. Common causes include residual monomers, plasticizer migration, antioxidant or colorant leaching, sterilant residues and contamination during manufacturing. Follow-up actions include extract dilution analysis, chemical characterization under ISO 10993-18 and reformulation or process modification to eliminate the offending leachable.
Does passing cytotoxicity testing prove full biocompatibility?
No. Cytotoxicity is only one endpoint within the biological evaluation plan defined by ISO 10993-1. Depending on the nature, duration and contact category of the device, additional tests such as sensitization, irritation, systemic toxicity, hemocompatibility, genotoxicity, subchronic toxicity and implantation may also be required.
Should samples be tested after sterilization?
Yes. Whenever possible, testing should reflect the final production condition, including the sterilization process used, whether ethylene oxide, gamma, electron beam or steam. Sterilization residues such as ethylene oxide and ethylene chlorohydrin should additionally be controlled in accordance with ISO 10993-7.